4.6 Editorial Material

Extensive heterogeneity in patients with ALS with mutations in SOD1 in France

Journal

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
Volume 92, Issue 9, Pages 914-914

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/jnnp-2021-326553

Keywords

ALS; neurogenetics

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Clinical Neurology

Misfolded SOD1 inclusions in patients with mutations in C9orf72 and other ALS/FTD-associated genes

Karin Forsberg, Karin Graffmo, Bente Pakkenberg, Markus Weber, Martin Nielsen, Stefan Marklund, Thomas Brannstrom, Peter Munch Andersen

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2019)

Article Medicine, General & Internal

Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

Timothy Miller, Merit Cudkowicz, Pamela J. Shaw, Peter M. Andersen, Nazem Atassi, Robert C. Bucelli, Angela Genge, Jonathan Glass, Shafeeq Ladha, Albert L. Ludolph, Nicholas J. Maragakis, Christopher J. McDermott, Alan Pestronk, John Ravits, Francois Salachas, Randall Trudell, Philip Van Damme, Lorne Zinman, C. Frank Bennett, Roger Lane, Alfred Sandrock, Heiko Runz, Danielle Graham, Hani Houshyar, Alexander McCampbell, Ivan Nestorov, Ih Chang, Manjit McNeill, Laura Fanning, Stephanie Fradette, Toby A. Ferguson

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Clinical Neurology

Deficits in verbal fluency in presymptomatic C9orf72 mutation gene carriers-a developmental disorder

Dorothee E. Lule, Hans-Peter Mueller, Julia Finsel, Patrick Weydt, Antje Knehr, Ivar Winroth, Peter Andersen, Jochen Weishaupt, Ingo Uttner, Jan Kassubek, Albert C. Ludolph

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2020)

Letter Clinical Neurology

Peripheral neuropathy in ALS: phenotype association

Mamede deCarvalho, Marta Gromicho, Peter Andersen, Julian Grosskreutz, Magdalena Kuzma-Kozakiewicz, Susanne Petri, Hilmi Uysal, Susana Pinto

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2021)

Article Clinical Neurology

Caregivers' divergent perspectives on patients' well-being and attitudes towards hastened death in Germany, Poland and Sweden

Peter M. Andersen, Magdalena Kuzma-Kozakiewicz, Juergen Keller, Anna Maksymowicz-Sliwinska, Krzysztof Barc, Krzysztof Nieporecki, Julia Finsel, Cynthia Vazquez, Olga Helczyk, Katharina Linse, Ann-Cristin Haggstrom, Erica Stenberg, Olof Semb, Katarzyna Ciecwierska, Natalia Szejko, Ingo Uttner, Andreas Herrmann, Susanne Petri, Thomas Meyer, Albert C. Ludolph, Dorothee Lule

Summary: The study found that caregivers significantly underestimated patients' well-being in Germany and Poland. In Sweden, there were just as many caregivers who underestimated and overestimated well-being. Despite cultural differences, there was a clear discrepancy between patients' and caregivers' perspectives on patients' well-being and preferences towards life.

AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2022)

Editorial Material Clinical Neurology

The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis

Kristiana Salmon, Matthew C. Kiernan, Seung H. Kim, Peter M. Andersen, Adriano Chio, Leonard H. van den Berg, Philip Van Damme, Ammar Al-Chalabi, Patricia Lillo, Jinsy A. Andrews, Angela Genge

BRAIN (2022)

Article Multidisciplinary Sciences

Neurofilaments can differentiate ALS subgroups and ALS from common diagnostic mimics

Arvin Behzadi, Fani Pujol-Calderon, Anton E. Tjust, Anna Wuolikainen, Kina Hoglund, Karin Forsberg, Erik Portelius, Kaj Blennow, Henrik Zetterberg, Peter Munch Andersen

Summary: Elevated levels of CSF NFL, CSF pNFH, and plasma NFL are significantly associated with ALS, providing diagnostic value in differentiating ALS from other neurological diseases. Plasma NFL levels can help differentiate between clinical and genetic subgroups of ALS. Survival rate is negatively correlated with all three biomarkers.

SCIENTIFIC REPORTS (2021)

Editorial Material Clinical Neurology

Pre-symptomatic spinal muscular atrophy: a proposed nosology COMMENT

Richard S. Finkel, Michael Benatar

Summary: Finkel and Benatar discuss the ambiguity of the term 'pre-symptomatic' in characterizing infants at genetic risk for spinal muscular atrophy, and propose a new conceptual framework.

BRAIN (2022)

Article Clinical Neurology

Mild motor impairment as prodromal state in amyotrophic lateral sclerosis: a new diagnostic entity

Michael Benatar, Volkan Granit, Peter M. Andersen, Anne-Laure Grignon, Caroline McHutchison, Stephanie Cosentino, Andrea Malaspina, Joanne Wuu

Summary: Amyotrophic lateral sclerosis (ALS) may evolve along a continuum and have a prodromal phase of mild motor impairment (MMI) that is often missed. Through studying pre-symptomatic gene mutation carriers, it is observed that mild motor impairment is an observable state that precedes clinically manifest ALS, providing potential for diagnosis and early therapeutic intervention.

BRAIN (2022)

Article Cell Biology

PEX11β and FIS1 cooperate in peroxisome division independently of mitochondrial fission factor

Tina A. Schrader, Ruth E. Carmichael, Markus Islinger, Joseph L. Costello, Christian Hacker, Nina A. Bonekamp, Jochen H. Weishaupt, Peter M. Andersen, Michael Schrader

Summary: This study reveals a novel pathway for peroxisome division and identifies the role of FIS1 in peroxisome division.

JOURNAL OF CELL SCIENCE (2022)

Review Clinical Neurology

Neurofilament light chain in drug development for amyotrophic lateral sclerosis: a critical appraisal

Michael Benatar, Joanne Wuu, Martin R. Turner

Summary: Interest in ALS biomarkers has increased significantly in the past 25 years, with the hope of using them to develop effective therapies. Neurofilament light chain (NfL) has emerged as a potential biomarker for ALS therapy development. The study discusses the evidence supporting the use of NfL in different clinical contexts, concluding that it can serve as a risk biomarker, a prognostic biomarker, and a pharmacodynamic biomarker.

BRAIN (2023)

Article Biochemistry & Molecular Biology

Mutant SOD1 aggregates formed in vitro and in cultured cells are polymorphic and differ from those arising in the CNS

Ulrika Nordstrom, Lisa Lang, Elaheh Ekhtiari Bidhendi, Per Zetterstroem, Mikael Oliveberg, Jens Danielsson, Peter M. Andersen, Stefan L. Marklund

Summary: This study identified two hSOD1 aggregate strains that can spread and cause fatal paralysis in adult transgenic mice. The spreading of these aggregates could be a primary disease mechanism in SOD1-induced ALS. The structure and amount of aggregates formed varied between different hSOD1 mutants and different cell lines. It is suggested that pathogenesis and therapeutic development should be conducted in models that replicate aggregate structures forming in the central nervous system.

JOURNAL OF NEUROCHEMISTRY (2023)

Article Clinical Neurology

Widespread CNS pathology in amyotrophic lateral sclerosis homozygous for the D90A SOD1 mutation

Karin M. Forsberg, Karin S. Graffmo, Erica Stenvall, Naima Tabikh, Stefan L. Marklund, Thomas Brannstrom, Peter M. Andersen

Summary: The D90A mutation in the SOD1 gene is associated with atypical features in amyotrophic lateral sclerosis, including slowly evolving motor symptoms, recessive heredity, and potential involvement of sensory, autonomic, and urinary bladder functions. This study reveals that neuropathological changes in patients with homozygous D90A mutation extend beyond the motor system to include cognitive and sensory cortical areas, but do not affect non-nervous organs.

ACTA NEUROPATHOLOGICA (2023)

Letter Clinical Neurology

Reply: A new diagnostic entity must enable earlier treatment in gene carriers

Michael Benatar, Ammar Al-Chalabi, Anita Crawley, Joanne Wuu

BRAIN (2023)

No Data Available